Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,348 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Completed No phase listed Observational

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

NCT02629081
View directory record Official record
Conditions
GERD
Interventions
Controls & Cases
Other
Lead sponsor
Loren Laine
Other
Eligibility
21 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Not applicable Interventional

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

NCT00002000
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 12:04 PM EDT
Active, not recruiting No phase listed Observational

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

NCT04710563
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 30, 2026, 12:04 PM EDT
Recruiting Phase 2 Interventional

Digoxin In NASH (CODIN)

NCT06588699
View directory record Official record
Conditions
NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions
Digoxin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults

NCT06659250
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06414300, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 12:04 PM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817
View directory record Official record
Conditions
Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Melanoma, Sarcoma, Solid Tumors
Interventions
Enapotamab vedotin (HuMax-AXL-ADC)
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 12:04 PM EDT
Recruiting No phase listed Observational

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

NCT04634643
View directory record Official record
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

NCT02893917
View directory record Official record
Conditions
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma With Neuroendocrine Differentiation, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Cediranib, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 2 Interventional

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

NCT06111768
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
Dapagliflozin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Suspended Phase 2 Interventional

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

NCT06050252
View directory record Official record
Conditions
Resectable Intrahepatic Cholangiocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Resection
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
57
States / cities
Irvine, California • Los Angeles, California • Orange, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Olaparib, Ramucirumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Corona, California • Duarte, California • Lancaster, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 3 Interventional

Neurosurgery Patient Outcomes in Treating Spinal Disorders

NCT01220921
View directory record Official record
Conditions
Symptomatic Lumbar Disc Herniation, Symptomatic Grade I Lumbar Spondylolisthesis
Interventions
Lumbar Discectomy, Single-level lumbar fusion
Procedure
Lead sponsor
Greenwich Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
San Francisco, California • Greenwich, Connecticut • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 30, 2026, 12:04 PM EDT
Active, not recruiting No phase listed Observational

OCS Heart Perfusion Post-Approval Registry

NCT05047068
View directory record Official record
Conditions
Transplant
Interventions
OCS Heart System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

NCT04856293
View directory record Official record
Conditions
Healthy Participants
Interventions
Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 30, 2026, 12:04 PM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
41
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Recruiting Not applicable Interventional

Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA

NCT02989948
View directory record Official record
Conditions
Aortic Aneurysm, Thoracoabdominal
Interventions
Physician-modified aortic endograft
Device
Lead sponsor
Yale University
Other
Eligibility
50 Years to 95 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
2
States / cities
New Haven, Connecticut • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 2 Interventional Results available

Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

NCT02487485
View directory record Official record
Conditions
Depression
Interventions
Ketamine, sirolimus, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Not applicable Interventional

High-dose Periop Statins for Prevention of DVT

NCT00259662
View directory record Official record
Conditions
Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions
atorvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 4 Interventional Results available

Standardized Treatment of Pulmonary Exacerbations II

NCT02781610
View directory record Official record
Conditions
Pulmonary Cystic Fibrosis
Interventions
Standard of care IV antibiotic(s)
Drug
Lead sponsor
Chris Goss
Other
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 30, 2026, 12:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Protein on Calcium Absorption and Gastric Acid Production

NCT00719160
View directory record Official record
Conditions
Osteoporosis
Interventions
esomeprazole, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 30, 2026, 12:04 PM EDT